by Avery Zimmerman | Jun 29, 2020 | Blog
By MMS Holdings and TrialAssure [Fill out the form below to access the whitepaper] While global regulatory authorities routinely update clinical trial disclosure and transparency requirements, new regulations set to take effect in 2020 and 2021 will dramatically...
by Avery Zimmerman | Feb 7, 2020 | Blog
The pharmaceutical industry—and healthcare in general—are in constant stages of innovation. According to the International Federation of Pharmaceutical Manufacturers & Associations, the number of new chemical or biological entities launched on the world market...
by Avery Zimmerman | May 9, 2019 | Blog
This complimentary lay summary whitepaper will explain: the ins and outs of lay summary writing, the importance of starting a pilot program, a checklist for lay reviewers, and strategic advice for becoming more transparent. Click on the image for the full...
by Avery Zimmerman | Mar 14, 2019 | Blog
Exerpt from whitepaper originally published by PhUSE on March 14, 2019 by project co-leads – Rashmi Dodia, MS, RAC and Gregory Campbell, BS Executive Summary Ever since policy 0070 was first introduced in 2016, there have been continuing concerns and challenges among...
by Avery Zimmerman | Nov 8, 2018 | Blog
Plain language summaries, commonly known as lay summaries, have become increasingly important for pharmaceutical companies in recent years. However, there are many sponsors that have yet to start their pilot programs for these documents. To answer some commonly-asked...
